

INFORMATION DISCLOSURE STATEMENT LIST  (Use as many sheets as necessary)		Complete if Known					
		Application Number		10/548,183			
		Filing Date		6/15/2006			
		First Named Inventor		Glickman, R.			
		Group Art Unit		3769			
		Examiner Name		Farah, Ahmed M			
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initials	Cite No.	Document No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
	B1	US 6,319,273 B1	11/20/2001	Chen, J			
	B2	US 6,443,976 B1	9/3/2002	Flower, R			
	B3	US-6,342,219 B1	1/29/2002	Thorpe, P			
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code	Date	Name	Translation Yes/No		
	B4	European Office Action for EP04718503.8 and Response	6/25/2008	Glickman, R			
	B5	WO 02/100326 A3	12/19/2002	Hasan, T			
	B6	WO 02/07819 A1	0/31/2002	Gomer, C			
	B7	WO 01/58240 A2	8/16/2001	Miller, J			
	B8	WO 03/039404 A2	5/15/2003	Guyer, D			
<b>NON-PATENT DOCUMENTS</b>							
Examiner Initials	Cite No.	Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication)					
	B9	Algvre P.V. <i>et al.</i> Age-related maculopathy: pathogenetic features and new treatment modalities. Acta Ophthalmologica Scandinavica 2002 United Kingdom, vol. 80, no. 2, 2002 p. 136-143					
	B10	Mayo G.L. <i>et al.</i> Antibody-targeted photodynamic therapy. American Journal of Ophthalmology 2003 United States, vol. 136, no. 6, 2005, p. 1151-1152					
	B11	Renno, R. <i>et al.</i> Selective Targeting of Verteporfin to Choroidal Neovascularization Mediated by a Homing Peptide to VEGF-R2. Invest Ophthalmol Vis Sci 43: Meeting Abstract 3977, 2002					
Examiner Signature: /Ahmed Farah/ (04/26/2009)		Date Considered: 04/26/2009					
EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							